KISQALI (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the KISQALI drug offered from Novartis Pharmaceuticals Corporation. This Kinase Inhibitor [EPC],Kinase Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
NON-PROPRIETARY NAME: | ribociclib |
SUBSTANCE NAME: | RIBOCICLIB |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Kinase Inhibitor [EPC],Kinase Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, FILM COATED |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2017-03-13 |
END MARKETING DATE: | 0000-00-00 |
KISQALI HUMAN PRESCRIPTION DRUG Details:
Item Description | KISQALI from Novartis Pharmaceuticals Corporation |
LABELER NAME: | Novartis Pharmaceuticals Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 200(mg/1) |
START MARKETING DATE: | 2017-03-13 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0078-0860_11364b70-4e7c-49de-8e2c-17c35a22e36f |
PRODUCT NDC: | 0078-0860 |
APPLICATION NUMBER: | NDA209092 |
Other RIBOCICLIB Pharmaceutical Manufacturers / Labelers: